gemcitabine + cisplatin + penpulimab

GP + Penpulimab is a chemo-immunotherapy combination regimen consisting of gemcitabine, a platinum-based chemotherapy agent (typically cisplatin), and penpulimab. Penpulimab is a humanized IgG1 monoclonal antibody targeting the programmed cell death-1 (PD-1) receptor. It is uniquely engineered with a modified Fc region to eliminate Fc gamma receptor (FcγR) binding, a design intended to minimize immune-related adverse events and prevent the depletion of PD-1-expressing T cells by macrophages. Gemcitabine and cisplatin act as cytotoxic agents that inhibit DNA synthesis and cause DNA cross-linking, respectively. This combination is primarily utilized as an induction therapy for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) to reduce tumor burden before concurrent chemoradiotherapy. Penpulimab was developed by Akeso Inc. in collaboration with Chia Tai-Tianqing Pharmaceutical Group.

Brand names

Anike

Other names

GP + PenpulimabGemcitabine + Cisplatin + PenpulimabGemcitabine + Platinum + Penpulimab